Picture of Biomx logo

PHGE Biomx Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Momentum

Relative Strength (%)
1m-27.49%
3m-50.11%
6m-54.49%
1yr-83.88%
Volume Change (%)
10d/3m-71.52%
Price vs... (%)
52w High-86.92%
50d MA-18.97%
200d MA-67.9%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-70.79%
Return on Equity-82.24%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Biomx EPS forecast chart

Profile Summary

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
November 1st, 2017
Public Since
December 14th, 2018
No. of Shareholders
72
No. of Employees
103
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNYSE MKT
Shares in Issue
29,982,282

PHGE Share Price Performance

Upcoming Events for PHGE

Q1 2023 Biomx Inc Earnings Release

FAQ

Or unlock with your email

Or unlock with your email